Sartorius Targets Biopharma Growth, Boosts Profitability Outlook

The company aims to consistently outgrow its addressable markets, projecting an organic sales revenue growth of 8% to 11% annually at the group level, significantly above the anticipated market growth of 7% to 9%. This growth is expected to be driven by its Bioprocess Solutions Division (9-12% annual sales increase) and Lab Products & Services Division (5-7% annual growth).

Concurrently, Sartorius is committed to expanding profitability, targeting an underlying EBITDA margin increase of 50 to 75 basis points per year for the group. Strategic initiatives include reinforcing leadership in core bioprocess applications, developing emerging businesses like advanced therapy solutions, and enhancing customer experience and operational efficiency.

CEO Dr. Michael Grosse emphasized the critical need for focus, innovation, and reliability in the evolving biopharma industry, where biologics are projected to comprise 57% of global pharma sales by 2030.